Respiratory Pharmacotherapy Use in Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in the UK: A Retrospective Cohort Study

2014 ◽  
Vol 11 (5) ◽  
pp. 521-530 ◽  
Author(s):  
Keele E. Wurst ◽  
Amit Shukla ◽  
Hana Muellerova ◽  
Kourtney J. Davis
2019 ◽  
Vol 7 ◽  
pp. 205031211984222 ◽  
Author(s):  
Salim Surani ◽  
Akshar Aiyer ◽  
Stephen Eikermann ◽  
Timothy Murphy ◽  
Pranav Anand ◽  
...  

Objectives: Over 380 million people in the world live with chronic obstructive pulmonary disease, and it is the third leading cause of death in the United States. Despite updated guidelines, there may be significant variations in diagnosis and management of chronic obstructive pulmonary disease at a primary care level. The aim of the study was to examine primary care physician management of chronic obstructive pulmonary disease in two community clinics. Methods: After approval from the Institutional Review Board, a retrospective chart review was done among all patients with the diagnosis of chronic obstructive pulmonary disease in two community clinics. Baseline demographics, utilization of spirometry, exacerbation history and home oxygen use were also obtained. Results: Chart reviews of 101 patients were completed (52 male and 49 female) in two outpatient primary care provider offices (Office A: 66 patients and Office B: 35 patients). None of the patients had validated measures of dyspnoea such as CAT or mMRC scores. Only 21% (22/101) of the patients had formal pulmonary function test testing done, and of those who had pulmonary function tests, 31.5% of patients were incorrectly diagnosed and mislabelled as chronic obstructive pulmonary disease. Pharmacotherapy for chronic obstructive pulmonary disease was not in alignment with GOLD guidelines, with only 42% of patients on an inhaler regimen that included a long-acting muscarinic antagonist. Conclusion: There is suboptimal use of pulmonary function test in a primary care setting for diagnosis of chronic obstructive pulmonary disease and substantial errors in diagnosis. There is virtually no use routinely of validated symptom scales for diagnosis of chronic obstructive pulmonary disease. There is substantial variance in pharmacotherapy, and regimens routinely do not follow GOLD guidelines.


2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Linda Lee ◽  
Tejal Patel ◽  
Loretta M. Hillier ◽  
James Milligan

Background. Chronic Obstructive Pulmonary Disease (COPD) is underdiagnosed in primary care.Aim. To explore the utility of proactive identification of COPD in patients 75 years of age and older in a Canadian primary care setting.Methods.Canadian Thoracic Society (CTS) screening questions were administered to patients with a smoking history of 20 pack-years or more; those with a positive screen were referred for postbronchodilator spirometry.Results. A total of 107 patients (21%), of 499 screened, had a 20-pack-year smoking history; 105 patients completed the CTS screening. Forty-four (42%) patients were positive on one or more questions on the screening; significantly more patients with a previous diagnosis of COPD (64%) were positive on the CTS compared to those without a previous diagnosis of COPD (30%). Of those who were not previously diagnosed with COPD (N= 11), four (36%) were newly diagnosed with COPD.Conclusion. A systematic two-stage method of screening for COPD, using CTS screening questions followed by spirometric confirmation, is feasible in the context of a busy primary care setting. More research is needed to assess the value of restricting screening to patients with a smoking history of 20 pack-years and on the sensitivity and specificity of these measures.


Sign in / Sign up

Export Citation Format

Share Document